Join us to learn how Genomenon is advancing Precision Therapeutics by unlocking Real-World Evidence (RWE) from decades of clinical literature.
Despite the vast trove of patient data and scientific insights contained in published research, extracting and organizing this information remains a significant challenge. Genomenon overcomes this challenge by combining genomics-focused AI with expert human curation and deep scientific expertise. This unique combination helps partners leverage this literature-driven RWE to drive discoveries that impact patient care and drug development.
During the session, we’ll take you through two case studies that show the breadth and depth of these insights, fueling everything from biomarker discovery and patient stratification to gene-disease curation and clinical trial design.
Rare Disease Use Case: Diagnostic Impact through Curation
Sarah Chang, Ph.D., Medical Strategy Lead at UCB, will detail how expert curation and classification of genetic variants in thymidine kinase 2 deficiency (TK2d) have expanded the disease’s knowledge base. Through meticulous expert curation, previously ambiguous or unrecognized variants are now clearly classified, providing the global clinical community with freely accessible, clinically actionable data. This resource not only accelerates accurate diagnosis but also reduces barriers to genetic testing, ultimately improving patient outcomes and informing care strategies.
Cancer Use Case: AI-Driven Insights for Drug Discovery
Dr. Mark Kiel, Genomenon Chief Scientific Officer, and Jonathan Eads, Genomenon VP of Technology, will demonstrate how Genomenon’s AI-powered knowledge graph indexes and analyzes clinical literature for RWE at scale. By intelligently linking therapies, phenotypes, genes, and variants across diverse disease areas, the platform enables comprehensive scientific analysis and precise patient characterization.
In one featured project, the platform processed over 50,000 full-text articles on colorectal cancer, uncovering novel correlations between patient demographics, genetic variants, treatments, and outcomes. These insights, including emerging biomarkers of immunotherapy response, provide actionable evidence that accelerates drug discovery and enables more targeted patient identification for precision therapeutics partners.
Broader Implications: Enabling Precision Therapeutics with Patient-Derived RWE
Whether the goal is to support the diagnosis of rare diseases or to drive targeted drug discovery in oncology, Genomenon enables partners to leverage patient-derived RWE from the literature. This capability positions therapeutic companies to make data-driven decisions, enhance precision medicine initiatives, and ultimately improve patient outcomes worldwide.
Join us to learn how your organization can apply these insights to your own drug development programs.
Thursday, June 26 at 11 AM ET/8 AM PT
Webinar recording coming soon!
